Pediatric Vaccines Market
Paediatric Vaccine Market: Pneumococcal Indication Segment Anticipated to Be the Most Attractive Segment Through 2026: Global Industry Analysis and Opportunity Assessment, 2016-2026
- 2016-12-05
- REP-GB-1317
- 194 pages
-
An Incisive, In-depth Analysis on the Pediatric Vaccines Market
This study offers a comprehensive, 360 degree analysis on the Pediatric Vaccines market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Pediatric Vaccines market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.
COVID -19 : Impact Analysis
Request the coronavirus imapact analysis across industries and markets
Request Covid -19 ImpactGlobal Paediatric Vaccine Market: Towards a better and safer tomorrow
Paediatric vaccines are administered to a child in its paediatric age which is from 0 – 18 years of age. Vaccines are generally given in order to prevent children from diseases transferred through infections, seasonal variations and even through unhygienic areas. Depending upon disease, the vaccines are administered at regular intervals. WHO has designed a standard immunization program in order to have desired time interval between vaccines doses.
Paediatric vaccines considered in the report include pneumococcal vaccine, DTP vaccine, rotavirus vaccine, MMR vaccine, polio vaccine, influenza vaccine, hepatitis B vaccine, Hib vaccine and meningococcal vaccine. Pneumococcal vaccine is administered to prevent the child from infectious diseases such as pneumonia. DTP vaccines is a combination vaccine administered against prevention of three diseases those are diphtheria, tetanus and pertussis. Hib vaccine is also a combination vaccine for hepatitis B and influenza and is widely accepted.
The market to expand manifold during the forecast period (2016 - 2026)
In terms of revenue, the global paediatric vaccine market is projected to expand at a CAGR of 12.2% during the forecast period and is expected to be valued at US$ 88.14 Bn by the end of 2026.
Revamped government policies to benefit the market, though soaring prices of vaccines to play spoilsport
The growth of the global paediatric vaccine market is primarily driven by increasing awareness regarding benefits of vaccination in prevention of diseases, rising economic growth, the collaboration of national manufacturers with key players in view to provide high-quality vaccines in at remote areas and initiative by global key players in developing innovative vaccines. In addition favourable reimbursement and increasing government support is expected to fuel the market growth over the forecast period. However, rising cost of vaccines, low accessibility to remote areas and increasing the availability of biosimilars at low rates might hinder the market growth over the forecast period.
The Pneumococcal segment to act as a catalyst in the overall market growth
Based on indication, the global paediatric vaccine market is segmented into pneumococcal vaccine, DTP vaccine, rotavirus vaccine, MMR vaccine, polio vaccine, influenza vaccine, hepatitis B vaccine, Hib vaccine and meningococcal vaccine. In terms of revenue share, the pneumococcal segment dominated the global paediatric vaccine market in 2015 and is expected to reach the cusp within the forecast period. The Hib segment is expected to witness relatively higher growth rates in terms of value in the global paediatric vaccine market over the forecast period.
Recombinant segment to face steep competition from the Conjugate segment within the forecast period
Based on technology, the global paediatric vaccine market is segmented into live or attenuated vaccine, inactivated or killed vaccines, conjugate vaccine, toxoid vaccine, subunit vaccine and recombinant vaccine. In terms of revenue share, the conjugate segment dominated the global paediatric vaccine market in 2015 and is expected to maintain the spike throughout the forecast period, registering higher CAGR as compared to the recombinant segment.
Monovalent vaccine segment to accumulate maximum market share
Based on vaccine type, the global paediatric vaccine market is segmented into monovalent vaccines and multivalent vaccines. Among these, monovalent vaccine segment held maximum market share in 2015 and expected to continue the trend throughout the forecast period.
The Institutional Health Centres segment to topple Hospital Pharmacy segment in the forecast period
Based on end user, the global paediatric vaccine market is segmented into hospital pharmacies, retail pharmacies and institutional health centres. Currently, institutional health centres segment accounts for relatively higher revenue share, followed by hospital pharmacy end user segment.
North America market to lead the pack
The global paediatric vaccine market is segmented into seven major regions: North America, Latin America, Western Europe, Eastern Europe, APEJ (Asia Pacific excluding Japan), Japan and the Middle East & Africa (MEA). In terms of value, North America is expected to be the dominant regional market by 2016 end and is expected to expand at a CAGR of 11.0% over the forecast period. APEJ is expected to be the fastest growing market in terms of revenue growth in the global paediatric vaccine market, registering a CAGR of 14.9% over the forecast period.
Key stakeholders to create clamour in the market through mergers and revamped investment policies
Some key players in the global paediatric vaccine market included in this report are GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Sanofi, Panacea Biotec, Zydua Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech and Indian Immunologicals Ltd.
Growing knowledge and awareness about the importance of pediatric vaccination and following pediatric vaccine schedules has been fostering growth for stakeholders in this landscape. Parents’ attitude towards children’s vaccinations and intentions are proving to be a favourable aspect for market players, triggering innovations in pediatric combination vaccines to eradicate various health disorders. Leading companies in the pediatric vaccines market are increasing focus on adopting advanced technologies such as conjugate vaccines, live or attenuated vaccines, recombinant vaccines, inactivated or killed vaccines, and subunit vaccines to further ensure efficacy of their offerings. However, market players will still have to grapple with the problem of vaccine hesitancy in many underdeveloped countries and some developing regions to expand their sales of pediatric vaccines in such highly populated landscapes with high birth rates.
Future Market Insights offers a 10-year forecast for the global paediatric vaccine market. The primary objective of the report is to offer updates and information related to market opportunities in the global dermatology devices market.
Report Description
The primary objective of the report is to offer insights on the market dynamics that can influence growth of the global paediatric vaccine market over the forecast period. Insights on key trends, drivers, restraints, value forecasts and opportunities for companies operating in the global paediatric vaccine market are presented in the report.
To understand and assess opportunities in this market, the report offers market forecast on the basis of indication, technology, vaccine type, end user and regions. The report provides analysis of the global paediatric vaccine market in terms of market value (US$ Mn).
Market Segmentation
|
Region |
Technology |
Indication |
End User |
Vaccine Type |
|---|---|---|---|---|
|
|
|
|
|
The report begins with the market definition, followed by definitions of the different indication of paediatric vaccine. The market dynamics section includes a comprehensive analysis on key trends, drivers, restraints, opportunities and macro-economic factors influencing the growth of the global paediatric vaccine market.
The next section of the report analyses the global paediatric vaccine market on the basis of technology and presents forecast in terms of value for the next 10 years. In addition, we have considered Year-on-Year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the global paediatric vaccine market.
In the final section of the report, a ‘competitive landscape’ has been included to provide a dashboard view of key companies operating in the global paediatric vaccine market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the global paediatric vaccine market and the potential players. However, this section also includes market strategies and SWOT analysis of the main players operational in the global paediatric vaccine market. Detailed profiles of paediatric vaccine manufacturers are also included in the scope of the report to evaluate their long- and short-term strategies.
What is our research methodology?
To deduce the market size of the global paediatric vaccine market, we have considered various viewpoints based on secondary research. Furthermore, data points such as regional split and market split in terms of services and parts, service provider, and vehicle type; and qualitative inputs from industry experts have been considered to arrive at suitable market estimates. The forecast presented in the report evaluates the actual revenue generated and expected revenue in the global paediatric vaccine market over the forecast period.
When developing the market forecast, the report begins with sizing the current market, which forms the basis for forecasting how the market is expected to grow during the forecast period. Given the characteristics of the market, we have triangulated the data on the basis of various analyses based on supply side, demand side, and other dynamics of the global paediatric vaccine market. Also, we understand the ever-fluctuating nature of the global economy and hence, we not only conduct forecasts in terms of CAGR, but also evaluate the market on the basis of key parameters such as year-on-year (Y-o-Y) growth to understand the predictability of the market and to identify growth opportunities for market players operating in the global paediatric vaccine market.
Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is usually overlooked, while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered by paediatric vaccine market. To understand key segments in terms of their growth and performance in the global paediatric vaccine market, Future Market Insights has developed a market attractiveness index. The resulting index would help providers identify existing market opportunities.
Analyst's Pick
Communicate and Connect
Secondary research plays a pivotal role in this research as the market is huge and it is constantly evolving with new innovations. We as a team not only searched for relevant information, but also spoke with some of the top honchos of vaccine manufacturing companies spread across the major healthcare economies of the world. This fetched some crucial and updated information about the market and provided a larger canvas to the research.
The striking point
The entire paediatric vaccine market is expected to surge within the forecast period. The North American region will lead the global growth of the paediatric vaccine market. But the blanket ban on MMR combination vaccine in Japan will have a massive impact on the market.
Combination vaccine: A new ray of hope
The combination vaccine is holding the key to growth for the global paediatric vaccine market. The combination vaccine will slash the rising cost of vaccines and it will also expand the global periphery of the paediatric vaccine market.
Get in touch
Harish Tiwari
Global Head - Business Development
Our Clients
CASE STUDIES
See how our work makes an impact.
At FMI, we design strategies that are adaptive, impactful, and implementable.